

CV Template of KATRD International Conference 2020

Name	Kye Young Lee	
Country	Korea	
Organization	Konkuk University Medical Center	
Current Position	Professor	

Educational Background

1997-1999	Post-Doctoral Research Fellow in Pulmonary and Critical Care Medicine Stanford University, School of Medicine, Palo Alto, CA, USA
1993-1997	Ph.D. in Internal Medicine Seoul National University, School of Medicine, Seoul, Korea
1988-1993	M.S. in Internal Medicine Seoul National University, School of Medicine, Seoul, Korea
1992-1993	Fellowship in Pulmonary Medicine Seoul National University, School of Medicine, Seoul, Korea
1985-1989	Intern and Residency in Internal Medicine Seoul National University Hospital, Seoul, Korea
1979-1985	B.S. in Medicine Seoul National University, School of Medicine, Seoul, Korea

Professional Experiences

2017-present	Chief and Professor Precision Medicine Lung Cancer Center, Konkuk University Medical Center, Seoul, Korea
2005-present	Professor Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea
1993-2005	Instructor, Assistant Professor, and Associate Professor Department of Internal Medicine, Dankook University School of Medicine, Cheonan, Korea

Professional Organizations

2019-present	CEO and Founder Exosignal, Inc.
2017-2018	Chair and CEO Korean Association of Lung Cancer (KALC)
2015-2016	Chair and Founder Korean Association for the Study of Target Therapy (KASTT)
2013-2014	Chair Molecular Lung Cancer Research Society, Korean Academy of Tuberculosis and Respiratory (KATRD)

Main Scientific Publications

- 1.Extracellular vesicle-based EGFR genotyping in bronchoalveolar lavage fluid from treatment-naïve non-small cell lung cancer patients. Hur JY, Lee JS, Kim IA, Kim HJ, Kim WS, **Lee KY**. Transl Lung Cancer Res. 2019 Dec;8(6):1051-1060
 - 2.Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA. Lee JS, Hur JY, Kim IA, Kim HJ, Choi CM, Lee JC, Kim WS, **Lee KY**. BMC Cancer. 2018 Dec 10;18(1):1236.
 - 3.Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma. Oh IJ, Hur JY, Park CK, Kim YC, Kim SJ, Lee MK, Kim HJ, **Lee KY**, Lee JC, Choi CM. Clin Lung Cancer. 2018 Sep;19(5):e775-e781.
 - 4.Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study. Kim IA, Lee JS, Kim HJ, Kim WS, **Lee KY**. BMC Cancer. 2018 Jul 28;18(1):768.
 - 5.Fluorometric detection of EGFR exon 19 deletion mutation in lung cancer cells using graphene oxide. Kim DM, Kim DH, Jung W, **Lee KY**, Kim DE. Analyst. 2018 Apr 16;143(8):1797-1804.
 - 6.Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients. Hur JY, Kim HJ, Lee JS, Choi CM, Lee JC, Jung MK, Pack CG, **Lee KY**. Mol Cancer. 2018 Jan 27;17(1):15.
 - 7.A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non-Small Cell Lung Cancer Patient. Lee JS, Hur JY, Kim HJ, **Lee KY**, Kim WS. J Thorac Oncol. 2017 Nov;12(11):e179-e181.
 - 8.Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid. Park S, Hur JY, **Lee KY**, Lee JC, Rho JK, Shin SH, Choi CM. Clin Chem Lab Med. 2017 Aug 28;55(10):1489-1495.
 - 9.Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non-Small-cell Lung Cancer: A TRAIL Trial. Park CK, Oh IJ, Kim KS, Choi YD, Jang TW, Kim YS, Lee KH, Shin KC, Jung CY, Yang SH, Ryu JS, Jang SH, Yoo SS, Yong SJ, **Lee KY**, In KH, Lee MK, Kim YC. Clin Lung Cancer. 2017 Jul;18(4):e289-e296.
 - 10.Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial. Oh IJ, Kim KS, Park CK, Kim YC, Lee KH, Jeong JH, Kim SY, Lee JE, Shin KC, Jang TW, Lee HK, **Lee KY**, Lee SY. BMC Cancer. 2016 Aug 26;16:690.
 - 11.Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer. Lee SE, Lee SY, Park HK, Oh SY, Kim HJ, **Lee KY**, Kim WS. J Korean Med Sci. 2016 Aug;31(8):1224-30.
-

12.The performance of a novel amino acid multivariate index for detecting lung cancer: A case control study in Korea. Kim HJ, Jang SH, Ryu JS, Lee JE, Kim YC, Lee MK, Jang TW, Lee SY, Nakamura H, Nishikata N, Mori M, Noguchi Y, Miyano H, **Lee KY**. Lung Cancer. 2015 Dec;90(3):522-7.

13.Clinical features of lung adenocarcinomas with epidermal growth factor receptor mutations and miliary disseminated carcinomatosis. Kim HJ, Kang SH, Chung HW, Lee JS, Kim SJ, Yoo KH, **Lee KY**. Thorac Cancer. 2015 Sep;6(5):629-35.

14.P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement. Kim HJ, **Lee KY**, Kim YW, Choi YJ, Lee JE, Choi CM, Baek IJ, Rho JK, Lee JC. BMC Cancer. 2015 Jul 29;15:553.

15.Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer. Geater SL, Xu CR, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, **Lee KY**, Palmer M, Shi Y, Lungershausen J, Wu YL. J Thorac Oncol. 2015 Jun;10(6):883-9.

16.Interactions between paraoxonase 1 genetic polymorphisms and smoking and their effects on oxidative stress and lung cancer risk in a Korean population. Eom SY, Yim DH, Lee CH, Choe KH, An JY, **Lee KY**, Kim YD, Kim H. PLoS One. 2015 Mar 5;10(3):e0119100.

17.Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, **Lee KY**, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Lancet Oncol. 2015 Feb;16(2):141-51.

18.Jung JH, Lee MY, Choi DY, Lee JW, You S, **Lee KY**, Kim J, Kim KP. Phospholipids of tumor extracellular vesicles stratify gefitinib-resistant nonsmall cell lung cancer cells from gefitinib-sensitive cells. Proteomics. 2015 Feb;15(4):824-35

19.Choi DY, You S, Jung JH, Lee JC, Rho JK, **Lee KY**, Freeman MR, Kim KP, Kim J. Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment. Proteomics. 2014 Aug;14(16):1845-56

20.Park JO, Choi DY, Choi DS, Kim HJ, Kang JW, Jung JH, Lee JH, Kim J, Freeman MR, **Lee KY**, Gho YS, Kim KP. Identification and characterization of proteins isolated from microvesicles derived from human lung cancer pleural effusions. Proteomics. 2013 Jul;13(14):2125-34